Life sciences

Project Hive Pet Company Announces Launch of its USA Made Dog Toy, Treat Company to Help Save the Bees

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, High-performance Integrated Virtual Environment, Molecular biology, Dark Skies, Bee, Pet, Hive, Biology, Articles, Life sciences

Project Hive Pet Company is a Public Benefit Company and a member of the Pet Sustainability Coalition dedicated to using business as a force for good.

Key Points: 
  • Project Hive Pet Company is a Public Benefit Company and a member of the Pet Sustainability Coalition dedicated to using business as a force for good.
  • Project Hive Pet Company Announces Launch of its USA Made Dog Toy, Treat Company to Help Save the Bees!
  • Jim Schifman, with his wife Melissa Rappaport Schifman, founded Project Hive Pet Company as a way to help save our home planet.
  • Project Hive Pet Company sells interactive dog toys and treats with a mission to save the bees.

Lyfegen platform supports Johnson & Johnson to further drive value-based healthcare strategy

Retrieved on: 
Tuesday, August 3, 2021
Johnson & Johnson, Healthcare in Switzerland, Companies, Life sciences, Health care

BASEL, Switzerland, Aug. 3, 2021 /PRNewswire/ -- Lyfegenannouncesthat itsvalue-based healthcare contracting platform has been implemented together with Johnson & Johnson Medical Devices Companies Switzerland (Johnson & Johnson) and a leading Swiss Hospital.

Key Points: 
  • BASEL, Switzerland, Aug. 3, 2021 /PRNewswire/ -- Lyfegenannouncesthat itsvalue-based healthcare contracting platform has been implemented together with Johnson & Johnson Medical Devices Companies Switzerland (Johnson & Johnson) and a leading Swiss Hospital.
  • Theshift towards avalue-based healthcare in Switzerland and globally can only be achieved through the support of innovative technologies.
  • The platform digitalisesand automates the execution ofvalue-based healthcare agreements, paving the way for the resource-efficient scaling of such novel agreements.
  • "saysLyfegen'sCEO, Girisha Fernando
    Lyfegen'scompliant, secure and patent-protected value-based healthcare contracting platform automates the collection and analysis of patient-level data.

Accelerate Diagnostics Announces CE Mark and Availability in Europe of Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems

Retrieved on: 
Tuesday, August 3, 2021
Articles, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Life sciences

This is an important new option for the Company's existing Accelerate PhenoTest BC kit, which already had an ID/AST configuration that is a fully integrated solution for labs needing both fast identification and fast AST.

Key Points: 
  • This is an important new option for the Company's existing Accelerate PhenoTest BC kit, which already had an ID/AST configuration that is a fully integrated solution for labs needing both fast identification and fast AST.
  • The Accelerate Pheno system has been shown to deliver improvements in clinical outcomes including time to results, time to optimal therapy, duration of therapy and hospital length of stay.
  • Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
    For more information about the company, its products and technology, or recent publications, visit axdx.com .

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at BTIG's Virtual Biotechnology Conference 2021

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Branches of biology, Natural sciences, Pharmaceutical industry, Biotechnology, Cytokines, Inflammasome, Biopharmaceutical, Medication, Efflux, Kidney

To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.

Key Points: 
  • To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease (VAR 200), please request a one-on-one meeting.
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.
  • Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/zyversa-therapeutics-ceo-stephe...

Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation

Retrieved on: 
Tuesday, August 3, 2021
Regeneron Pharmaceuticals, Tarrytown, New York, Life sciences, Biotechnology, Monoclonal antibodies, Industry economics)

TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 3, 2021 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research.
  • Each winner received $50,000 in prize money, along with a $5,000 donation to their institution, and ten additional finalists were awarded $5,000 each.
  • "This year's winners and finalists once again demonstrated the power and innovative spirit of the next generation of scientists.
  • For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology, Health sciences, Hepatitis, Non-alcoholic fatty liver disease, Biopharmaceutical, Liver

Synthetic Biologics previously announced an option agreement with MGH to negotiate an exclusive license to IP and technology for the use of SYN-020 to prevent and treat metabolic and inflammatory diseases associated with aging.

Key Points: 
  • Synthetic Biologics previously announced an option agreement with MGH to negotiate an exclusive license to IP and technology for the use of SYN-020 to prevent and treat metabolic and inflammatory diseases associated with aging.
  • The option agreement has now been expanded to include technology developed by MGH to use SYN-020 to inhibit liver fibrosis in select diseases, including NAFLD.
  • Under the terms of the amended agreement, Synthetic Biologics is granted an option to negotiate an exclusive worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging and fibrosis of the liver.
  • Synthetic Biologics recently announced the completion of patient dosing and observation of its Phase 1 single-ascending dose ("SAD") clinical trial of SYN-020 in 24 healthy adult volunteers.

Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Business Update

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Cyclacel, Biotechnology, Articles, Biopharmaceutical

BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update onWednesday, August 11, 2021.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.(NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter financial results and provide a business update onWednesday, August 11, 2021.
  • Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology.
  • This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel.

Clene to Present at Canaccord Genuity's Annual Growth Conference

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Articles, Biotechnology, Nanomedicine, Nanotechnology, Biopharmaceutical

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that its management team will be presenting at Canaccord Genuity's 41st Annual Growth Conference.

Key Points: 
  • SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that its management team will be presenting at Canaccord Genuity's 41st Annual Growth Conference.
  • A webcast of the presentation will be available on the Events and Presentations section of the Clene website.
  • Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, is leading the way by using nanotechnology to treat energetic failure, which underlies many neurological diseases.
  • Clene has innovated a novel nanotherapeutic platform to create a new class of drugs.

iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021

Retrieved on: 
Tuesday, August 3, 2021
Companies, Health care, Life sciences

and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10, 2021 at 2:20 p.m.

Key Points: 
  • and GOSSELIES, Belgium, Aug. 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the upcoming Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10, 2021 at 2:20 p.m.
  • iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.
  • iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
  • iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Health sciences, Health care, Antiviral drugs, Orphan drugs, Brincidofovir, Ebola, Prodrugs, Biopharmaceutical, Glioma

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.

Key Points: 
  • DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m.
  • Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and an efficacy analysis by blinded independent central review is expected later in 2021.